• ABOUT ELITE
    • Overview
    • Our Facility
    • Management & Key Employees
    • Our Board
    • Careers
  • PRODUCTS
  • PIPELINE
    • Generic
    • Branded
  • TECHNOLOGY
    • Technology Overview
    • How It Works
    • One Bead System
    • Two Bead System
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Shareholder Meeting
    • Governance Documents
    • Investor Contacts
    • Email Alerts
logo image
HOME | CAREERS | CONTACT | NEWS |
Share
Skip to content
  • About Elite
    • Overview
    • Management & Key Employees
    • Our Board
    • Careers
  • Products
  • Pipeline
    • Generic
    • Branded
  • Technology
    • Technology Overview
    • How It Works
    • One Bead System
    • Two Bead System
  • Investor Relations
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Shareholder Meeting
    • Governance Documents
    • Investor Contacts
    • Email Alerts
    • Investor Relations
    • Press Releases
    • Events &
      Presentations
    • SEC Filings
    • Shareholder
      Meeting
    • Governance
      Documents
    • Investor Contacts
    • Email Alerts

Press Releases
 
Select:
Dec 22, 2022
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
Nov 15, 2022
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information
Nov 08, 2022
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2023 Financial Results on November 15, 2022
Nov 02, 2022
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Aug 15, 2022
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information
Aug 11, 2022
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2023 Financial Results on August 16, 2022
Jun 29, 2022
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information
Jun 29, 2022
Elite Pharmaceuticals Receives FDA Approval for Generic Sabril®
Jun 23, 2022
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2022 Financial Results on June 30, 2022
May 11, 2022
Elite Pharmaceuticals, Inc. Appoints Robert Chen as Chief Financial Officer
 1   2   3     4    5   6   7   8   9 
 <<   <   >   >> 
  • Site Map   |  Privacy  |  Terms Of Use
Copyright © Elite Pharmaceuticals Inc. | All Rights Reserved.
ART™: Abuse-Resistant Technology for a safer healthier you.
Back to top

Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window